Home › Funds › Pivotal bioVenture Partners Investment Advisor LLC › ARQT
Pivotal bioVenture Partners Investment Advisor LLC position in ARQT
ARCUTIS BIOTHERAPEUTICS INC · Health Care
Pivotal bioVenture Partners Investment Advisor LLC reported holding 1,008,174 shares of ARQT (ARCUTIS BIOTHERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$26.6M, representing 10.86% of its reported portfolio and ranking #2 among its reported holdings. Pivotal bioVenture Partners Investment Advisor LLC has disclosed ARQT holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-11-14 · Source: SEC EDGAR Form 13F-HR
How Pivotal bioVenture Partners Investment Advisor LLC's ARQT position evolved
Pivotal bioVenture Partners Investment Advisor LLC first disclosed a stake in ARQT in Q3 2023 at 1,105,309 shares (US$5.9M). The position peaked in Q3 2025 at 2,120,508 shares, worth US$40.0M. Across 13 filings, Pivotal bioVenture Partners Investment Advisor LLC increased the stake 4 time(s), trimmed it 4 time(s) and left it unchanged 4 time(s). The most recent filing (Q3 2026) shows 1,008,174 shares valued at US$26.6M — a reduction of -257,109 shares quarter over quarter.. Notable position changes include a 73% increase in Q4 2023 (shares rose 207% over the following quarter), a 36% trim in Q4 2025 (shares fell 19% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 1.11M | $5.87M | New |
| Q4 2023 | 1.91M | $6.17M | Add |
| Q1 2024 | 2.03M | $20.10M | Add |
| Q2 2024 | 2.04M | $18.98M | Add |
| Q3 2024 | 2.12M | $19.72M | Add |
| Q4 2024 | 2.12M | $29.54M | Hold |
| Q1 2025 | 2.12M | $33.16M | Hold |
| Q2 2025 | 2.12M | $29.73M | Hold |
| Q3 2025 | 2.12M | $39.97M | Hold |
| Q4 2025 | 1.37M | $39.69M | Reduce |
| Q1 2026 | 1.36M | $31.94M | Reduce |
| Q2 2026 | 1.27M | $33.18M | Reduce |
| Q3 2026 | 1.01M | $26.65M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About ARQT and 13F data
ARQT (ARCUTIS BIOTHERAPEUTICS INC) is a Health Care company. 45 other funds we track also report a position in ARQT — the largest reported positions include MONTANOVA CAPITAL, LLC (US$326.1M), Frazier Life Sciences Management, L.P. (US$258.9M), Rubric Capital Management LP (US$216.9M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding ARQT
- MONTANOVA CAPITAL, LLC 12.44M sh · $326.10M · Q2 2026
- Frazier Life Sciences Management, L.P. 9.87M sh · $258.91M · Q2 2026
- Rubric Capital Management LP 8.27M sh · $216.88M · Q2 2026
- ORBIMED ADVISORS LLC 2.04M sh · $53.54M · Q2 2026
- OBERWEIS ASSET MANAGEMENT INC/ 1.37M sh · $36.00M · Q2 2026
- Simplify Asset Management Inc. 865.86K sh · $22.88M · Q3 2026
More on Pivotal bioVenture Partners Investment Advisor LLC
FAQ
How long has Pivotal bioVenture Partners Investment Advisor LLC held ARQT?
Pivotal bioVenture Partners Investment Advisor LLC has disclosed ARQT holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
What is Pivotal bioVenture Partners Investment Advisor LLC's current position in ARQT?
As of Q3 2026, Pivotal bioVenture Partners Investment Advisor LLC holds 1.01M shares of ARQT (ARCUTIS BIOTHERAPEUTICS INC), valued at $26.65M, representing 10.86% of its reported portfolio and ranking #2.
Has Pivotal bioVenture Partners Investment Advisor LLC been buying or selling ARQT?
In the latest 13F filing (Q3 2026), Pivotal bioVenture Partners Investment Advisor LLC reduced its position in ARQT. The position peaked in Q3 2025 at 2.12M shares.
Which other funds hold ARQT?
Other major institutional holders of ARQT include MONTANOVA CAPITAL, LLC, Frazier Life Sciences Management, L.P., Rubric Capital Management LP, among 45 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.